55,489 Shares in Definium Therapeutics, Inc. $DFTX Purchased by GSA Capital Partners LLP

GSA Capital Partners LLP acquired a new position in shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) in the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 55,489 shares of the company’s stock, valued at approximately $654,000. GSA Capital Partners LLP owned approximately 0.07% of Definium Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in DFTX. Russell Investments Group Ltd. boosted its stake in shares of Definium Therapeutics by 110.4% in the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after acquiring an additional 2,003 shares during the last quarter. CWM LLC lifted its holdings in Definium Therapeutics by 67.4% in the 2nd quarter. CWM LLC now owns 4,459 shares of the company’s stock valued at $29,000 after purchasing an additional 1,796 shares in the last quarter. Fifth Third Bancorp boosted its stake in Definium Therapeutics by 5,593.2% during the 3rd quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock worth $40,000 after purchasing an additional 3,300 shares during the last quarter. Sound Income Strategies LLC purchased a new stake in shares of Definium Therapeutics during the third quarter worth $46,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of Definium Therapeutics by 56.0% during the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after buying an additional 3,020 shares in the last quarter. Institutional investors and hedge funds own 27.91% of the company’s stock.

Definium Therapeutics Stock Performance

NASDAQ:DFTX opened at $17.13 on Monday. The company’s 50-day moving average is $15.16 and its two-hundred day moving average is $12.59. Definium Therapeutics, Inc. has a 1-year low of $4.70 and a 1-year high of $18.70. The company has a debt-to-equity ratio of 0.31, a current ratio of 3.30 and a quick ratio of 3.30. The firm has a market capitalization of $1.69 billion, a price-to-earnings ratio of -8.40 and a beta of 2.57.

Insiders Place Their Bets

In related news, CEO Robert Barrow sold 25,791 shares of the firm’s stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $339,151.65. Following the completion of the sale, the chief executive officer directly owned 778,477 shares of the company’s stock, valued at approximately $10,236,972.55. This trade represents a 3.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Daniel Karlin sold 5,600 shares of the business’s stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $13.15, for a total transaction of $73,640.00. Following the completion of the sale, the insider owned 425,025 shares in the company, valued at approximately $5,589,078.75. This trade represents a 1.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 42,667 shares of company stock valued at $561,071 over the last quarter. 2.26% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on DFTX shares. Needham & Company LLC reissued a “buy” rating on shares of Definium Therapeutics in a research note on Monday, January 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Definium Therapeutics in a report on Thursday, January 22nd. JonesTrading began coverage on Definium Therapeutics in a report on Tuesday, December 23rd. They set a “buy” rating and a $61.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Definium Therapeutics in a research report on Monday, February 2nd. Finally, Royal Bank Of Canada increased their price target on Definium Therapeutics from $20.00 to $36.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $35.22.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.